Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$213.3MCash on Hand
25.6mo Cash Runway
Follow NKTX by emailGet an email when NKTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NKTX, unsubscribe in one click. Privacy
📣 What NKTX Says Is Next
in 2026 · “Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026”
Company press release, Aug 10, 2026 · SEC filing
in 2026 · “Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026”
Company press release, May 12, 2026 · SEC filing
fourth quarter · “Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 25, 2026 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025.”
Company press release, Mar 25, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Clinical trial Nkarta reported initial Ntrust data for NKX019 in myositis and systemic sclerosis: 5 of 6 myositis patients at 4 billion cells achieved moderate or major TIS responses, and 6 of 7 systemic sclerosis patients achieved rCRISS-25 or greater. No CRS, ICANS, IEC-HS or GvHD was reported among 40 patients. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Clinical trial Announced a November 9, 2026 webcast at 8:00 a.m. ET to review initial clinical data for NKX019 in myositis and systemic sclerosis from the Ntrust program, to be presented at ACR Convergence 2026. The filing furnishes the press release. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Earnings Reported Q3 2026 results: cash, equivalents and investments of $216.0 million at September 30, 2026, expected to fund operations into 2029. R&D expense was $29.5 million and G&A $6.3 million, with a net loss of $33.3 million, or $0.45 per share. Initial NKX019 clinical data will be presented at ACR Convergence 2026. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Earnings Reported Q2 2026 results: cash of $243.2 million at June 30, 2026, funding operations into 2029. Net loss was $40.4 million, or $0.54 per share, including $8.0 million of impairment charges. R&D expenses were $29.0 million and G&A expenses were $14.1 million. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 1/2 · Recruiting · A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) Registry primary completion date, not a results date
Oct 2028 · Phase 1/2 · Recruiting · A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not NKTX's own candidates): Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NKTX holds $213.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $25M/quarter from operations,
an estimated runway of 25.6 months at that rate (BioRadar estimate, not company guidance).
Share count 71,704,404 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NKTX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NKTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.